ClinicalTrials.gg
RecruitingNCT02855476HDClarityUpdated Apr 27, 2026

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

An observational study in Huntington's Disease, sponsored by University College, London. Recruiting at 40 sites in 10 countries. Open to participants aged 11 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by University College, London · Observational

How we know

From the registry’s dates

  • Started Jan 2017; still recruiting 9 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
11 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Huntington Disease with a site in United Kingdom — 10 open to participants now, 15 under way, 3 of them phase 3. Huntington Disease · United Kingdom.

Planned enrollment
3rd of 13
2,500 · median 154
Started
2017
with 3 others
Observational
13 of 51
4 open now
Primary completion
2027-04
later than 4 of 14 live
Registered
18th of 51
by date
Lead sponsor
2 of 51
University College, London

Among the 51 studies in Huntington Disease with a site in United Kingdom, this one is the 3rd largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2017, is one of 13 observational ones, reaches primary completion later than 4 of the 14 other live ones, and was the 18th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

10 of the 51 studies in Huntington Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 11 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Huntington Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.

Read the detailed description

This is a longitudinal open-ended observational study. Participants will attend two annual study visits, an Annual Screening Visit followed by an Annual Sampling Visit, and may also attend an optional visit during the first year of enrollment, an Optional Repeat Sampling Visit.

During the Annual Screening Visit, medical history, and clinical and phenotypic data will be obtained. Participants who meet the eligibility requirements of the study and are willing to continue in the study, will return for an Annual Sampling Visit. During that visit, biosamples will be collected following a fast of at least 6 hours, or overnight: blood will be obtained via venipuncture and CSF will be obtained via lumbar puncture. Some participants may be invited to return for an Optional Repeat Sampling Visit approximately 4-8 weeks after the Annual Sampling Visit during their first year of enrolment.

The annual visits are at regular intervals after the first Annual Screening Visit (i.e. at 1, 2, 3 years and so on) ± 2 months. Participants will be encouraged to complete all annual visits; however, they are under no obligation to take part and will be able to skip annual visit without being discontinued from the study. Participants who do not come for an Annual Sampling Visit for three consecutive years will be discontinued from the study, but they may enrol again at a later date, if they so consent. Participants who have already completed HDClarity Sampling Visits under earlier versions of this protocol may also participate in the longitudinal study if they meet the eligibility criteria.

03

Conditions studied

  • Huntington's Disease

Browse trials for

04

Who can participate

Ages eligible
11 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants across 8 clinical cohorts will be enrolled at multiple sites up to an estimated minimum of 2500 participants or until the study is terminated by either the Funding Source or Sponsor

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age (18-75 years controls, early/late premanifest HD and incomplete penetrance HD, 21-75 years early/moderate/advanced manifest HD, ≥11 years juvenile HD)
  • Enroll HD participant
  • Capable of consenting or have a legal representative (parent/guardian for juveniles)
  • Capable of complying with study procedures
  • All participants other than family and community controls must have had a genetic test for HD

Exclusion criteria

Exclusion Criteria:

  • Drug trial within 30 days of any sampling visit
  • Changes in medication (antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD within 30 days)
  • Antiplatelet or anticoagulant therapy within 14 days
  • Significant comorbidity
  • Needle phobia, headache, spinal surgery / deformity
  • Clotting or bruising disorder
  • Screening blood test abnormalities >10% outside normal range
  • Drug / alcohol abuse
  • Positive urine pregnancy test at any screening or sampling visit for females of
  • Predictable non compliance or unwillingness
  • Serious adverse event related to HDClarity study procedures or any lumbar puncture procedure performed for any reason in the previous 30 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Early Pre-manifest HD

    Participants eligible are persons who meet the following criteria: 1. Are 18-75 years of age, inclusive, at the time of consent; and 2. Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score \< 4; and 3. Have CAG expansion ≥ 40; and 4. Have burden of pathology score, computed as (CAG - 35.5) × age, \< 250

  • Late Pre-manifest HD

    Participants eligible are persons who meet the following criteria: 1. Are 18-75 years of age, inclusive, at the time of consent; and 2. Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score \< 4; and 3. Have CAG expansion ≥ 40; and 4. Have burden of pathology score, computed as (CAG - 35.5) x age, ≥ 250

  • Early Manifest HD

    Participants eligible are persons who meet the following criteria: 1. Are 21-75 years of age, inclusive, at the time of consent; and 2. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and 3. Have CAG expansion ≥ 40; and 4. Have Stage I or Stage II HD, defined as UHDRS Total Functional Capacity (TFC) scores between 7 and 13 inclusive

  • Moderate Manifest HD

    Participants eligible are persons who meet the following criteria: 1. Are 21-75 years of age, inclusive, at the time of consent; and 2. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and 3. Have CAG expansion ≥ 40; and 4. Have Stage III HD, defined as UHDRS TFC scores between 3 and 6, inclusive

  • Advanced Manifest HD

    Participants eligible are persons who meet the following criteria: 1. Are 21-75 years of age, inclusive, at the time of consent; and 2. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and 3. Have CAG expansion ≥ 40; and 4. Have Stage IV HD, defined as UHDRS TFC scores between 0 and 2, inclusive

  • Incomplete Penetrance HD

    Participants eligible are persons who meet the following criteria: 1. Are 18-75 years of age, inclusive, at the time of consent; and 2. Have CAG expansion of 36-39

  • Juvenile Manifest HD

    Participants eligible are persons who meet the following criteria: 1. Are ≥11 years of age at the time of consent; and 2. Have clinical diagnostic features of juvenile HD, defined as UHDRS Diagnostic Confidence Score = 4 aged ≤20 years; and 3. Have CAG expansion ≥ 40

  • Healthy Control

    Participants eligible are persons who meet the following criteria: 1. Are 18-75 years of age, inclusive, at the time of consent; and 2. Have no known family history of HD; or 3. Have known family history of HD but have been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD (CAG \< 36).

06

What researchers measure

Primary outcomes

  1. The primary objective of this study is:

    To generate a high quality CSF sample collection for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD.

    Time frame: years N/A

Secondary outcomes

  1. The secondary objectives of this study are:

    To generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development. To collect phenotypic and clinical data for each participant.

    Time frame: years N/A

07

Study locations

32 of 40 sites recruiting
  • Cenexel
    Englewood, Colorado, United States
    Recruiting
  • Georgetown University
    Washington D.C., District of Columbia 20057, United States
    Recruiting
    • Erin Koppel · Contactek875@georgetown.edu · 202-687-1525
    • Karen Anderson, MD · Principal investigator
  • John Hopkins University
    Baltimore, Maryland 21287, United States
    Recruiting
    • Susan Robinson · Contactsrobin95@jhmi.edu · 410-955-1349
    • Jee Bang, MPH, MD · Principal investigator
  • Wake Forest University
    Winston-Salem, North Carolina 27109, United States
    Completed

    Not enrolling at this site — choose another above.

  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
    Recruiting
  • University of Texas Health Science Center
    Houston, Texas 77030, United States
    Recruiting
  • University of British Columbia, The Centre for Huntingtons Disease
    Vancouver, British Columbia V6T 2B5, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Ottawa Hospital
    Ottawa, Ontario K1Y 4E9, Canada
    Recruiting
    • Jane Ding · Contactjading@toh.ca
    • Tiago Mestre, Dr · Principal investigator
  • North York General Hospital
    Toronto, Ontario M2K 1E1, Canada
    Recruiting
  • Centre for Movement Disorders
    Toronto, Ontario M3B 2S7, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Centre Hospitalier Universitaire d'Angers
    Angers, 49000, France
    Recruiting
    • Audrey Olivier · Contactauolivier@chu-angers.fr · +33 241355615
    • Christopher Verny, Dr · Principal investigator
  • Le Centre Hospitalier Universitaire de Bordeaux
    Bordeaux, 33076, France
    Recruiting
  • University Hospital Ulm
    Ulm, Baden-Wurttemberg 89081, Germany
    Recruiting
  • Dresden University
    Dresden, Saxony 01307, Germany
    Recruiting
    • Stefan Bräuer · ContactStefan.Braeuer@ukdd.de · 351- 458 2524
    • Bjoern Falkenburger, MD · Principal investigator
  • St Josef And Elisabeth Hospital
    Bochum, 44791, Germany
    Recruiting
  • University Hospital of Erlangen
    Erlangen, 91054, Germany
    Recruiting
  • George Huntington Institute
    Münster, 48149, Germany
    Recruiting
  • Kbo-Isar-Amper-Klinikum Taufkirchen (Vils)
    Taufkirchen, 84416, Germany
    Recruiting
    • Michael Bachmaier · ContactMichael.Bachmaier@kbo.de · 08084-934-417
    • Alzbeta Mühlbäck, MD, PhD · Principal investigator
  • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
    Milan, 20133, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Lega Italiana Ricera Huntington
    Rome, 00185, Italy
    Recruiting
    • Paola Mina · Contactpaola.mina@lirh.it
    • Ferdinando Squitieri, MD · Principal investigator
  • The University of Auckland
    Grafton, Auckland 1023, New Zealand
    Recruiting
    • Christina Buchanan · ContactCBuchanan@adhb.govt.nz · +64 9 307 4949
    • Richard Roxburgh, Prof · Principal investigator
  • NZ Brain Research Institute
    Christchurch, Canterbury 8011, New Zealand
    Recruiting
  • Institute of Psychiatry and Neurology
    Warsaw, 02-957, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Gulbenkian Institute of Molecular Medicine
    Lisbon, 1649-028, Portugal
    Recruiting
  • Cruces University Hospital
    Bilbao, Biscay 48903, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital de Sant Pau
    Barcelona, 08041, Spain
    Recruiting
    • Sofia Bonavita · ContactSBonavita@santpau.cat · +34 932919000
    • Jamie Kulisevsky, MD, PhD · Principal investigator
  • Ramón y Cajal Universitary Hospital
    Madrid, 28034, Spain
    Recruiting
  • Royal Devon & Exeter NHS Foundation Trust
    Exeter, Devon EX2 5DW, United Kingdom
    Recruiting
    • Julie Moss · Contactjulie.moss10@nhs.net · 01392408181
    • Tim Harrower, MBBS · Principal investigator
  • Glasgow Clinical Research Facility
    Glasgow, Scotland G51 4TF, United Kingdom
    Recruiting
  • Birmingham Huntingtons Disease Clinic
    Birmingham, West Midlands B15 2 FG, United Kingdom
    Recruiting
    • Elsa Benn · Contacte.benn@nhs.net · 0121 301 2363
    • Hugh Rickards, MB, ChB, MSc, FRCPsych, MD · Principal investigator
  • North Bristol NHS Trust
    Bristol, BS10 5NB, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge, CB2 0PY, United Kingdom
    Recruiting
    • Katie Andresen · Contactkera2@cam.ac.uk · 01223 331141
    • Roger Barker · Principal investigator
  • Cardiff University
    Cardiff, CF24 4HQ, United Kingdom
    Recruiting
  • Fife Health Board - Whyteman's Brae Hospital
    Kirkcaldy, KY1 2ND, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Leeds Teaching Hospital Trust
    Leeds, LS7 4SA, United Kingdom
    Recruiting
  • The Walton Centre NHS Foundation Trust
    Liverpool, L9 7LJ, United Kingdom
    Recruiting
    • Jenni Burns, BSc MSc · Contactjenni.burns3@nhs.net
    • Rhys Davies, MA BM BCh PhD FRCP · Principal investigator
  • University College London Hospitals NHS Foundation Trust
    London, NW1 2PG, United Kingdom
    Recruiting
    • Opeyemi Kinyomi · Contacto.kinyomi@ucl.ac.uk · 0203 108 2638
    • Edward Wild, MD, PhD · Principal investigator
  • St George's University Of London
    London, SW17 0RE, United Kingdom
    Recruiting
  • Oxford University Hospitals NHS Foundation Trust
    Oxford, OX3 9DU, United Kingdom
    Recruiting
    • Zara Skitt · Contactzara.skitt@ouh.nhs.uk · 01865 234309
    • Richard Armstrong, MA, PhD, BMBCh, MRCP · Principal investigator
  • University Hospitals Plymouth NHS Trust
    Plymouth, PL6 5FP, United Kingdom
    Recruiting
    • Elizabeth Cray · Contactelizabethcray@nhs.net · 01752 439636
    • Daniel Lashley, MBBS · Principal investigator
08

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The cerebrospinal fluid (CSF) and plasma samples collected in this study will be the basis of future biomarker analysis studies. A Scientific Advisory Committee which will decide how the samples will be analysed.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2017 (actual). Primary completion is estimated for Apr 2027, 123 months after the start.

Of 34 observational studies under Huntington Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 34. This study's planned 123 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2016
First posted
Aug 4, 2016
StartActual
Jan 1, 2017
Primary completionEst.
Apr 30, 2027
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02855476
Collaborators
CHDI Foundation, Inc.
Responsible party
Edward Wild (Dr, University College, London) — Principal investigator
First posted
Aug 4, 2016
Start date
Jan 1, 2017
Primary completion
Apr 30, 2027 (estimated)
Last update
Apr 27, 2026

Study contacts

Katarzyna Schubert, PhD
Contact
hdclarity-cc@enroll-hd.org
Gail Owen, PhD
Contact
g.owen@ucl.ac.uk
+44 1273 640 688
Edward J Wild, MA, MB BChir, MRCP, PhD
principal investigator · University College, London

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion